Corporate Profile
Basic Information
| Company Name | Mitsubishi Tanabe Pharma Corporation |
|---|---|
| Capital Stock | 50 billion yen |
| President&Representative Director | UENO Hiroaki |
| Headquarters | 3-2-10, Dosho-machi, Chuo-ku, Osaka 541-8505, Japan TEL: 81-6-6205-5085 |
| Number of Employees | 6,728 (Consolidated) 3,383 (Non-consolidated）（As of March 31, 2021） |
| Incorporated | December 13, 1933 |
| Date of Merger | October 1, 2007 |
Business Activities
Pharmaceuticals
Manufacture and sale of pharmaceuticals, centered on ethical drugs
Major Ethical Drugs
| Central nervous system | Lexapro, Uplizna | |
|---|---|---|
| Immuno-inflammation | Stelera, Simponi, Imusera | |
| Vaccines | Influenza vaccine, TETRABIK, varicella vaccine, Mearubik, JEBIK V | |
| Others | Diabetes and kidney | Tenelia, Canaglu, Canalia, Vafseo |
| Allergy | Rupafin | |
Major OTC Drugs
| Agent for treatment of skin conditions | Flucort f, Cort f series |
|---|---|
| Digestive medicine | Tanabe ichoyaku〈choritsu〉, Tanabe ichoyaku urso, Cerekinon S |
| Digestive drink | Urso ukon |
| Nutrient and tonic drink | Aspara drink α |
| Allergic rhinitis medication | Talion AR |
